...
首页> 外文期刊>Digestive Diseases and Sciences >Gastrointestinal Tolerability of Metamizol, Acetaminophen, and Diclofenac in Subchronic Treatment in Rats
【24h】

Gastrointestinal Tolerability of Metamizol, Acetaminophen, and Diclofenac in Subchronic Treatment in Rats

机译:亚他莫唑,对乙酰氨基酚和双氯芬酸在大鼠亚慢性治疗中的胃肠道耐受性

获取原文
获取原文并翻译 | 示例
           

摘要

The gastrointestinal tolerability of metamizol and acetaminophen [weak cyclooxygenase (COX) inhibitors] in comparison with diclofenac (nonselective cyclooxygenase inhibitor) was evaluated in subchronic treatments in rats. Wistar rats recived 60 mg/kg body weight of metamizol and acetaminophen, and 3 mg/kg body weight of diclofenac by oral route twice daily for 14 days. Myeloperoxidase activity, an index of neutrophil infiltration, COX expression and the effects on blood parameters used as indicators of liver and renal functions were also studied. Metamizol and acetaminophen did not cause apparent gastrointestinal lesions; in contrast diclofenac showed swelling and an increased thickness on the distal intestinal mucosa. Myeloperoxidase activity was significantly increased in the small bowel with diclofenac treatment. In gastric mucosa the expression of the cyclooxygenase-1 was not affected and the expression of cyclooxygenase-2 was not observed. Diclofenac treatment significantly diminished hematocrit, hemoglobin, and corpuscular volume and increased the number of platelets. Aspartate aminotransferase and γ-glutamyltransferase activity were also altered and, regarding the renal biochemical parameters, the animals treated with diclofenac had increased urea values. In contrast, acetaminophen treatment did not affect either of these parameters and metamizol increased only the alanine aminotransferase activity. Under our experimental conditions, metamizol and acetaminophen seem to be safe drugs. In contrast, with diclofenac treatment blood loss and anemia are observed which could stem from the small intestinal injury. Moreover, this drug could to impair kidney function.
机译:在大鼠的亚慢性治疗中,评估了美他唑和对乙酰氨基酚[弱环加氧酶(COX)抑制剂]与双氯芬酸(非选择性环加氧酶抑制剂)的胃肠道耐受性。 Wistar大鼠通过口服途径每天两次两次服用60 mg / kg体重的间苯二酚和对乙酰氨基酚和3 mg / kg体重的双氯芬酸。还研究了髓过氧化物酶活性,中性粒细胞浸润指数,COX表达以及对血液参数的影响,这些指标被用作肝肾功能的指标。美他唑和对乙酰氨基酚均未引起明显的胃肠道损害。相反,双氯芬酸在远端肠粘膜上显示肿胀和厚度增加。双氯芬酸治疗后,小肠中的髓过氧化物酶活性显着增加。在胃粘膜中,环氧合酶-1的表达未受影响,并且未观察到环氧合酶-2的表达。双氯芬酸治疗可显着减少血细胞比容,血红蛋白和红细胞体积,并增加血小板数量。天冬氨酸氨基转移酶和γ-谷氨酰转移酶活性也发生了改变,就肾脏生化参数而言,用双氯芬酸治疗的动物尿素值升高。相反,对乙酰氨基酚治疗不影响这两个参数,并且美他唑仅增加丙氨酸转氨酶的活性。在我们的实验条件下,美他唑和对乙酰氨基酚似乎是安全的药物。相反,用双氯芬酸治疗可观察到失血和贫血,这可能是由于小肠损伤引起的。而且,这种药物可能损害肾功能。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号